{
    "nctId": "NCT02715466",
    "officialTitle": "Prospective, Controlled, Double-Blind, Randomized Multicentric Study On The Efficacy And Safety Of An Early Target Controlled Plasma Volume Replacement Therapy With A Balanced Gelatine Solution vs A Balanced Electrolyte Solution In Patients With Severe Sepsis",
    "inclusionCriteria": "* Male or female patients \u2265 18 years of age\n* Women of child bearing potential must test negative on standard pregnancy test (urine or serum)\n* Patients with body weight \u2264 140 kg\n* Patients diagnosed severe sepsis / septic shock at admission on Intensive Care Unit who can be enrolled within 90 min after admission OR patients diagnosed severe sepsis / septic shock during Intensive Care Unit stay who can be enrolled within 90 min after diagnosis\n* Patients where antibiotic therapy has already been started (prior to randomization)\n* Patient who are fluid responsive. Fluid responsiveness is defined as increase of \\> 10% in mean arterial pressure (MAP) after passive leg raising (PLR)\n* Signed informed consent by patient, legal representative or authorized person or deferred consent\n* Must have minimum age of 18 Years\n* Must have maximum age of 85 Years",
    "exclusionCriteria": "* Administration of HES, dextrane solutions or \\> 500 ml of Gelatin solutions within the 24 h prior to randomization\n* Death expected within the next 48 h (moribund patients as defined by ASA \u2265 class V)\n* Patients for whom the need of pressure infusions are expected\n* Patients with confirmed acute SARS-CoV-2 (COVID-19) infection (as available from routine medical records/ patient chart)\n* Requirement for renal support (either continuous or discontinuous techniques, including intermittent haemodialysis, haemofiltration and haemodiafiltration)\n* Patients receiving therapeutic heparin medication due to chronic coagulation disease / anticoagulation medication (i.e. partial thromboplastin time \\> 60 sec)\n* Acutely burned patients\n* Contraindications according to summary of product characteristics of investigational test and reference product\n* Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)"
}